Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
Janus kinase-signal transducers and activators of transcription (JAK-STAT) signaling is critical to multiple cellular processes, including survival, differentiation, and proliferation. JAK-STAT signaling dysregulation has been noted in inflammatory disorders, and aberrant JAK2 pathway activation has...
Guardado en:
Autores principales: | Jack W Singer, Suliman Al-Fayoumi, Jason Taylor, Sharlene Velichko, Alison O'Mahony |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0a6c4642fce44293bfd6aac30fb1e078 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Ruxolitinib as an emerging treatment in myelofibrosis
por: Emanuel RM, et al.
Publicado: (2013) -
Ruxolitinib: a targeted treatment option for patients with polycythemia vera
por: Vaddi K, et al.
Publicado: (2016) -
Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date
por: Bassiony S, et al.
Publicado: (2020) -
Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma.
por: Fani Karagianni, et al.
Publicado: (2021) -
Mechanistic-empirical pavement design guide: features and distinctive elements
por: Martínez Díaz,Margarita, et al.
Publicado: (2015)